Insilico Medicine IP Limited

Glaxosmithkline Intellectual Property Development Limited

Shanghai Medicilon Inc.

Medicilon Preclinical Research (shanghai) Llc.

Glaxo Group Limited

Huawei Technologies Co., Limited

Feng Ren

Xiao Ding

Xichen Lin

Baowei Zhao

Jianyu Xu

Liena Qin

Chunlin Chen

Jinna Cai

Weiqiang Xing

Hailong Wang

Yingxia Sang

Hongfu Lu

Yang Zhan

Xianlian Wang

Yongmei Xu

Qian Liu

Hui Lei

Xin Zhi Ma

Ting Yang

Weichun Chen

Zhongmiao Xu

Ebere F Igboko

Paul Bryan Wren

Wei Zhu

Jose Luis Castro Pineiro

Zehong Wan

Wei Cai

Robert W Marquis, Jr

Zhibin Zheng

David Robert Vesey

Xin Cheng

Luoheng Qin

Yan A Ivanenkov

Yun Jin

Luigi Piero Stasi

Yuehua Chen

Jing Deng

Jingjing Peng

Jinxin Liu

Xiaoyu Ding

Bogdan Zagribelnyy

Yueying Ren

Yubin Lv

Bangliang Li

Yangchun Luo

Lindong Zhu

Huaxing Yu

Xiaosong Liu

Chiachun Chen

Jianfei Wan

Lingdong Zhu

Guanghui Deng

Kevin Meng

The invention relates to an indole derivative shown in general formula (I-1) and its use in preparing drugs for preventing and/or treating indications of S1P receptor related disorders. The indole derivative of the invention is replaced by R, R, R, and Rat different sites respectively, and the obtained modified indole derivative has excellent biological activity and is an ideal S1P receptor regulator with high efficiency. Compounds of general formula (I-1) can be used to treat and/or prevent Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, multiple sclerosis, atopic dermatitis, eosinophilic esophagitis, alopecia areata, primary cholangitis, pyoderma gangrenosum, graft-versus-host disease, amyotrophic lateral sclerosis, systemic lupus erythematosus, type I diabetes arteriosclerosis, atherosclerosis, scleroderma, autoimmune hepatitis, acne, microbial infection, viral infection, and other autoimmune and inflammatory diseases.

Indole derivative and application thereof

A class of substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseases is described as represented by the following formula (I):

Substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseases

A novel type of pyrrolopyrazole derivatives shown in general formula (I), a preparation method thereof and application thereof or a pharmaceutical composition containing same as a therapeutic agent, particularly as a gastric acid secretion inhibitor and a potassium-competitive acid blocker (P-CABs) in biomedicine.

Pyrrolopyrazole derivatives, preparation method thereof and application thereof in medicine

Disclosed are a pyrrolopyrazole derivative, a preparation method therefor, and the medical use thereof. In particular, disclosed are a novel class of pyrrolopyrazole derivatives represented by general formula (I), a preparation method therefor, and the use of the pyrrolopyrazole derivatives or pharmaceutical compositions containing the pyrrolopyrazole derivatives in biomedicine as therapeutic agents, particularly as gastric acid secretion inhibitors and potassium ion competitive acid blochers (P-CABs). The definitions of various substituent (R, R, R, R) and the group (X) in general formula (I) are the same as the definitions in the description.

Described herein are PHD inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of anemia.

Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof

The disclosure provides for compounds and methods for modulating or inhibiting TEAD. Further provided herein are pharmaceutical compositions comprising the TEAD inhibitors and methods of treatment using the TEAD inhibitors or the pharmaceutical compositions.

TEAD inhibitors and methods of uses thereof

Described herein are KAT6A inhibitors of Formula (Ia) and pharmaceutical compositions comprising said inhibitors. The subject compounds of Formula (Ia) and compositions are useful for the treatment of a disease or disorder associated with KAT6A

Lysine acetyltransferase 6A (KAT6A) inhibitors and uses thereof

Described herein are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.

Diacylglycerol kinase (DGK) alpha inhibitors and uses thereof

Described herein are PHD inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of inflammatory bowel disease.

Described herein are MAT2A inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with MAT2A.

Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof

Provided herein are compounds, pharmaceutical compositions, and methods for treating a SARS-CoV-2 infection.

SARS-CoV-2 inhibitors for treating coronavirus infections

Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved. 

Compounds for inhibiting LRRK2 kinase activity

Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.

Substituted fused pyrazole compounds and their use as LRRK2 inhibitors

Growing community of inventors

Shanghai, China

Feng Ren